Specialist interests:
Peritoneal Malignancy
Training and education:
Assigned Educational Supervisor for Foundation trainees
Examiner for FRCS
I am a certified mentor for the European School of Peritoneal Surface Oncology
Experience:
Clinical Director HHFT General Surgery and Urology 2017 to 2021.
2018-2020 Peritoneal Malignancy Specialist Advisor to NICE involved in publication of updated colorectal cancer guidelines 2020.
2021 Appointed to Clinical Governance Board of the Association of Coloproctology of Great Britain and Ireland (ACPGBI).
Member of Association of Surgeons of Great Britain and Ireland and Association of Coloproctology of Great Britain and Ireland.
Research:
Research activity
I have helped design and am co-investigator in 2 randomised controlled trials of fibrinogen concentrate in cytoreductive surgery for pseudomyxoma peritonei.
2020 to 2023 Biotest £1.5 million : Adjusted Fibrinogen Replacement Strategy AdFirst trial.
2024 to date CSL-Behring £2 million : Randomised Phase 3 Single centre non inferiority study comparing RIASTAP (Human Fibrinogen Concentrate) with cryoprecipitate for the treatment of acquired fibrinogen deficiency.
I designed and am Principal Investigator of the HIPEC-PMP trial (opened December 2024 with £1.16 million funding) leading the first UK Randomised controlled trial evaluating Mitomycin C (MMC) dosing during Hyperthermic intraperitoneal chemotherapy following cytoreductive surgery for pseudomyxoma peritonei, a rare cancer arising from the appendix. This is in partnership with Southampton Clinical Trials Unit who selected us through a competitive process.
26 peer-reviewed papers published since 2021, h-index 48
